+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Cancer Supportive Care Drugs Market by Therapeutic Class (Antiemetics, Bisphosphonates, Erythropoiesis Stimulating Agents), Application (Breast Cancer, Colorectal Cancer, Liver Cancer) - Forecast 2024-2030

  • PDF Icon

    Report

  • 180 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5715521
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cancer Supportive Care Drugs Market size was estimated at USD 20.62 billion in 2023, USD 21.46 billion in 2024, and is expected to grow at a CAGR of 4.50% to reach USD 28.06 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Supportive Care Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Supportive Care Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Supportive Care Drugs Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Group PLC, Amgen Inc., Aphios Corporation, AstraZeneca PLC, Bayer AG, Celldex Therapeutics, GSK PLC, Helsinn Healthcare SA, Heron Pharma, Ipsen Pharma, Johnson & Johnson, Merck & Co., Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Cancer Supportive Care Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Therapeutic Class
    • Antiemetics
    • Bisphosphonates
    • Erythropoiesis Stimulating Agents
    • Granulocyte-Colony Stimulating Factors
    • Non-Steroidal Anti-Inflammatory Drugs
    • Opioids
  • Application
    • Breast Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
    • Stomach Cancer
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Cancer Supportive Care Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Supportive Care Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Cancer Supportive Care Drugs Market?
  4. What is the market share of the leading vendors in the Cancer Supportive Care Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Cancer Supportive Care Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer Supportive Care Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer coupled with increase in the geriatric population
5.1.1.2. Increasing approval and launch of new products
5.1.1.3. Increase in R&D activities for development of cancer supportive care drugs
5.1.2. Restraints
5.1.2.1. High cost of cancer supportive care drugs
5.1.3. Opportunities
5.1.3.1. Development of novel targeted therapies for the treatment of cancer
5.1.3.2. Rising adoption of biosimilar and increasing government expenditure on healthcare
5.1.4. Challenges
5.1.4.1. Side effects associated with consumption of drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cancer Supportive Care Drugs Market, by Therapeutic Class
6.1. Introduction
6.2. Antiemetics
6.3. Bisphosphonates
6.4. Erythropoiesis Stimulating Agents
6.5. Granulocyte-Colony Stimulating Factors
6.6. Non-Steroidal Anti-Inflammatory Drugs
6.7. Opioids
7. Cancer Supportive Care Drugs Market, by Application
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Liver Cancer
7.5. Lung Cancer
7.6. Prostate Cancer
7.7. Stomach Cancer
8. Americas Cancer Supportive Care Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Cancer Supportive Care Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Cancer Supportive Care Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Acacia Pharma Group PLC
12.1.2. Amgen Inc.
12.1.3. Aphios Corporation
12.1.4. AstraZeneca PLC
12.1.5. Bayer AG
12.1.6. Celldex Therapeutics
12.1.7. GSK PLC
12.1.8. Helsinn Healthcare SA
12.1.9. Heron Pharma
12.1.10. Ipsen Pharma
12.1.11. Johnson & Johnson
12.1.12. Merck & Co.
12.1.13. Novartis International AG
12.1.14. Sanofi SA
12.1.15. Sun Pharmaceutical Industries Ltd.
12.1.16. Teva Pharmaceutical Industries Ltd.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. CANCER SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER SUPPORTIVE CARE DRUGS MARKET DYNAMICS
FIGURE 7. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
FIGURE 8. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned

  • Acacia Pharma Group PLC
  • Amgen Inc.
  • Aphios Corporation
  • AstraZeneca PLC
  • Bayer AG
  • Celldex Therapeutics
  • GSK PLC
  • Helsinn Healthcare SA
  • Heron Pharma
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck & Co.
  • Novartis International AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information